178 results about "Severe anaemia" patented technology

The invention relates to the technical field of microorganisms, and discloses Ackermann muciniphila, a combined microbial agent thereof and application of the Ackermann muciniphila in inflammatory enteritis. The invention provides Akkermansia muciniphila AIML-559, and the preservation number of the Akkermansia muciniphila AIML-559 is CGMCC (China General Microbiological Culture Collection Center) No. 34246. The invention relates to a combined microbial agent, which is characterized by comprising Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34300). The combined microbial agent is prepared from the following raw materials: Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 The ackermann mucophil combined microbial inoculum is suitable for treatment intervention of inflammatory bowel disease (IBD), and can relieve weight loss, hemolysis, anemia, diarrhea, intestinal bleeding and other symptoms of IBD mice.

Methods for treating patients with wAIHA comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

Provided herein are crystalline salt and free base forms and amorphous forms of a compound having the following formula (I): (I) Compound 1. Also provided are pharmaceutical compositions comprising such crystalline and amorphous forms, processes for their manufacture and their use for the treatment of various conditions such as hemolytic anemia, sickle cell disease and MDS (very low risk MDS, low risk MDS, lower risk MDS and / or moderate risk MDS).

The invention provides an anti-anemia traditional Chinese medicine composition as well as a preparation method and application thereof. The anti-anemia traditional Chinese medicine composition is prepared from lithocarpus litseifolius, fructus gardeniae and rhizoma gastrodiae. The main active component dihydrochalcone (such as phlorizin, trilobatin, phloretin and the like) of lithocarpus litseifolius can improve iron metabolism by regulating a hepcidin-iron transporter axis; gardenoside in gardenia can target the liver to optimize iron distribution, and gastrodia elata polysaccharide can regulate immunity and improve the marrow microenvironment; the three forms a full-chain regulation and control network of intestinal tract iron absorption, liver iron utilization and bone marrow hematopoiesis microenvironment together, and the anti-anemia effect is enhanced in multiple dimensions.

The invention relates to a turnip juice containing probiotics that helps to resolve intestinal problems, supports the immune and cardiovascular systems, reduces cancer risk, protects the liver and kidneys, has antidiabetic effects, supports skin and hair health, reduces anemia, prevents osteoporosis, and possesses antimicrobial properties, as well as a method for producing this turnip juice.

The present invention relates to daprodustat or a pharmaceutically acceptable salt thereof for use in reducing fatigue in a specific population of non-dialysis subjects with anemia associated with chronic kidney disease, characterized by baseline hepcidin and hsCRP levels.

The present disclosure relates to 1-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl)-4- hydroxypyrrolidine-2-carboxamide derivatives and structurally related compounds of formula (I) as VHL inhibitors for the treatment of e.g. anemia (e.g. chronic anemia or anemia associated with chronic kidney disease, dialysis or cancer chemotherapy), ischemia, stroke or injury to the cardiovascular system during ischemia, or for enhancing wound healing, reducing scarring or enhancing angiogenesis or arteriogenesis.

The invention provides a composition with an effect of improving iron-deficiency anemia as well as a preparation method and application of the composition, and belongs to the technical field of pharmaceutical compositions. The composition with the effect of improving iron-deficiency anemia, provided by the invention, is prepared from the following raw materials in parts by weight: 15 to 20 parts of radix astragali seu hedysari extract, 5 to 10 parts of fructus jujubae extract, 2 to 5 parts of radix paeoniae alba extract, 4 to 8 parts of radix angelicae sinensis extract and 8 to 16 parts of ethylenediaminetetraacetic acid ferric sodium salt. The defect of single effect in the prior art is broken through, the synergistic effect of the four effects of improving iron-deficiency anemia, helping sleep, improving acne and protecting gastric mucosa is achieved through scientific compatibility, the conditioning requirements of crowds with multiple diseases can be met without taking multiple products, the eating burden is reduced, meanwhile, the antagonistic effect among different product components is avoided, and the health-care product is suitable for being popularized and applied. The overall conditioning effect can be improved.

The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for treating transfusion-dependent β-thalassemia.

The disclosure relates to a molecule that inhibits BAFF pathway, particularly an antibody or a binding fragment thereof, particularly an anti-BAFF-R antibody, e.g. ianalumab, for use in the treatment of autoimmune hemolytic anemia (AIHA), in particular, warm autoimmune hemolytic anemia (wAIHA).

The application discloses application of aza-3 in resisting erythroleukemia, wherein the aza-3 is a compound obtained by modifying a ring of aza-3 with 3alpha-O-(Boc-proline); the application proves that the aza-3 can obviously inhibit HEL and K562 cell proliferation, reduce splenomegaly, improve anemia indexes (RBC, HGB and HCT) and splenic and hepatic pathological infiltration, and has no obvious toxic side effects on main organs such as heart, lung and kidney through in-vitro MTT experiment and a Friend virus-induced erythroleukemia mouse model.

Provided herein is the use of particular dose levels or amounts of certain pyruvate kinase activators or pharmaceutically acceptable salts or compositions thereof, for treating anemia associated with low risk MDS, lower risk MDS and / or intermediate risk MDS (collectively, LRMDS) and other conditions.

The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with the expression of the TMPRSS6 gene or inhibit its expression and to therapeutic uses such as for the treatment of hemochromatosis, porphyria and hematological disorders such as β-thalassemia, sickle cell disease and iron overload from transfusions or myelodysplastic syndrome.

There remains a need for effective therapeutic agents for the treatment of TGFβ superfamily-associated disorders. [Solution] Polypeptides comprising an activin receptor type IIB (ActRIIB) ectodomain (ECD) variant are provided. In some embodiments, the polypeptides of the present disclosure comprise an ActRIIB-ECD variant fused to an Fc domain portion. The present disclosure also provides pharmaceutical compositions and methods using the polypeptides to treat diseases and conditions associated with TGF-β superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (e.g., anemia).

In the field of gene therapy, a major hurdle is the design and identification of constructs and gene therapy vectors providing therapeutic effects while displaying satisfactory safety profiles. In the treatment of Diamond-Blackfan Anemia (DBA), therapies alleviating several crucial anemia symptoms, such as blood or bone marrow cellularity, hemoglobin levels, erythrocytes levels, or platelet levels, while showing satisfactory safety profiles remain a challenge. The present invention provides constructs encoding ribosomal protein genes involved in DBA, such as genes encoding RPS19, RPS17, RPS24, RPS10, RPL35a, RPL11, RPS26, and RPL5, vectors, methods, cells, and medical uses thereof, addressing these challenges and finding particular applications in the field of autologous cell therapy treatment of DBA. Further, the present invention provides a non-genotoxic conditioning protocol for preparing a subject prior to cell therapy treatment for DBA using construct of the present invention.

The invention relates to the technical field of medicines, in particular to application of huperzine A in treatment of beta-thalassemia. It is found for the first time that the anti-Alzheimer disease drug huperzine A can be directly combined with gamma-globin to inhibit degradation of gamma-globin through a ubiquitin-proteasome pathway, so that the stability of gamma-globin and the fetal hemoglobin level are improved; the abnormal erythropoiesis and hemolysis phenotype of the beta-thalassemia are improved under the condition of not changing the mRNA expression. Animal experiments show that huperzine A obviously improves hematocrit and the number of red blood cells, reduces the size distribution width of the red blood cells and the proportion of reticulocytes, relieves oxidative stress, hemolysis, splenomegaly and iron overload, and has no obvious liver and kidney toxicity. The invention creatively provides a new strategy for improving HbF by regulating and controlling protein homeostasis instead of transcriptional up-regulation, and provides a new drug action mechanism and application direction for treatment of beta-thalassemia and other hemoglobin diseases.

The invention belongs to the technical field of health-care food, and provides gel soft sweets for improving iron-deficiency anemia and a preparation method thereof, and the gel soft sweets comprise the following raw materials in parts by mass: 5-7 parts of an extract, 9-11 parts of compound gum and 2-4 parts of a sugar solution. According to the product, longan aril, angelica sinensis, fructus lycii, dried ginger, Chinese yam and honey-fried licorice root are used as functional components, carrageenan and agar are compounded to form a gel, erythritol is used as a sugar solution, and the functional gel soft sweets which have unique fragrance of traditional Chinese medicinal materials, are fine and smooth in texture and good in palatability and are easily accepted by the public are developed. Based on the characteristic that the medicinal and edible extract has a blood replenishing function, the candy has the effects of improving weight loss, hemoglobin content reduction and the like of people suffering from iron-deficiency anemia.

The application belongs to the technical field of drug screening, and particularly relates to a method for applying oxalic acid to high-throughput screening of drugs for preventing and treating anemia related to abnormal differentiation of erythroid cells. The application provides application of oxalic acid in screening of drugs for preventing and treating anemia related to abnormal differentiation of erythroid cells and a high-throughput drug screening method. The application uses oxalic acid to detect hematin, has the characteristics of high sensitivity and high accuracy, can be used to construct a high-throughput drug screening output system, significantly reduces the cost of drug screening, and improves the screening efficiency and accuracy.

The invention relates to the technical field of functional food, in particular to a polypeptide composition for regulating menstruation and nourishing blood and a preparation method thereof, and the polypeptide composition comprises the following raw materials: a Chinese wolfberry extract, an astaxanthin-fish oil co-coated preparation, a red algae oligosaccharide iron complex, maltodextrin and folic acid. In the polypeptide composition for regulating menstruation and nourishing blood and the preparation method thereof, the astaxanthin-fish oil co-coated preparation stably wraps the strong antioxidant astaxanthin and the fish oil through a complex coacervation microencapsulation technology, so that excessive free radicals generated by menstrual physiological stress can be efficiently eliminated, inflammatory response of uterine tissues can be relieved, and discomfort symptoms such as dysmenorrhea and the like can be relieved; according to the red algae oligosaccharide iron complex, oligosaccharide is used as a natural carrier of an iron element and is absorbed in an oligosaccharide iron chelating form in intestinal tracts, the absorption way of traditional ferric salt is avoided, the bioavailability is greatly improved, the iron element can be efficiently and mildly supplemented, and iron-deficiency anemia is improved.

The present invention provides compositions and methods of treating and improving the symptoms of AIHA using an antibody or antigen-binding fragment thereof that specifically binds human CD19.

Methods for the treatment of disorders associated with mitochondrial dysfunction, including rare, inborn errors of metabolism caused by genetic mutations; neurodegenerative disease; diabetes; and aging and age-associated decline. Generally, the methods include administering a therapeutically effective amount of one or more treatments that (i) induce hemoglobin “left-shifting” and / or (ii) induce anemia, as described herein, to a subject who is in need of, or who has been determined to be in need of, such treatment.

The invention belongs to the technical field of drainage devices, and discloses a pericardial effusion drainage device which comprises an extracorporeal membrane lung oxygenation therapeutic apparatus and a fixing device. The extracorporeal membrane lung oxygenation therapeutic apparatus comprises a main control table, an artificial membrane lung, a centrifugal pump and an oxygenator, an inlet and an outlet of the centrifugal pump are connected with a first catheter and a second catheter respectively, the first catheter is connected with veins of a patient, the free end of the second catheter is connected with the artificial membrane lung, the artificial membrane lung is connected with a third catheter, and the third catheter is connected with the oxygenator. The free end of the third catheter is connected with the artery or vein of the patient; a branch tube of the first catheter is connected with a hydrops catheter, the free end of the hydrops catheter is connected with a drainage tube, and the diameter of the hydrops catheter is smaller than that of the drainage tube. The technical problems that according to an existing drainage mode, effusion cannot be continuously drained, the drainage efficiency is low, the postoperative anemia risk can be increased for a patient with blood loss due to an operation, and the recovery cycle of the patient is prolonged are solved.

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating myelodysplastic syndrome and related complications thereof. The traditional Chinese medicine composition comprises sculellaria barbata, astragalus membranaceus, angelica sinensis, nightshade, radix curcumae, red ginseng, duchesnea indica, saussurea involucrata, cyclea verticillata and salvia miltiorrhiza. The traditional Chinese medicine composition has a good prevention and treatment effect on myelodysplastic syndrome and related complications thereof, can effectively inhibit proliferation of hematological tumor cells, and also can inhibit proliferation of the myelodysplastic syndrome by increasing the hemoglobin level, reducing the inflammatory cytokine level and reducing the proportion of peripheral blood T cells. Anemia, inflammation and low immune function caused by the myelodysplastic syndrome can be treated. The invention provides an effective strategy for prevention or treatment of myelodysplastic syndrome and related complications thereof, and provides a new direction for application of the traditional Chinese medicine composition.

The invention provides a composition and food helpful for preventing and / or improving anemia and application of the composition and the food. The composition comprises beta-casein and a poria cocos extract, and the mass ratio of the beta-casein to the poria cocos extract is (0.2-60): 1. The composition can improve anemia symptoms, and can effectively improve the anemia state by promoting generation of red blood cells, promoting hematopoietic function recovery and increasing the hemoglobin content and realizing multiple regulation mechanisms.

The present invention provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate). The formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate) may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. The present invention further provides methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate). The formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate) may be administered conjointly with other FDA- approved drugs such as luspatercept, lenalidomide, erythropoiesis-stimulating agents (ESAs), including but not limited to epoetin alfa or darbepoetin alfa, and / or a hypomethylating agent, such as azacitidine and / or decitabine.

This invention relates to the field of biomedical technology, and more particularly to a CD47-targeting degradation polypeptide compound and its applications. The CD47-targeting degradation polypeptide compound provided by this invention can specifically bind to the CD47 protein on the surface of tumor cells and induce its direct degradation. The polypeptide compound of this invention can target and degrade the CD47 protein on the surface of tumor cells, exhibiting excellent anti-tumor effects without significant toxic side effects, avoiding drawbacks such as blood toxicity, anemia, and thrombocytopenia. It has good biocompatibility and has significant development and application value in the preparation of anti-tumor drugs, and can be used to develop anti-tumor polypeptide drugs.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.

The invention provides an oral preparation for improving anemia after gastric resection operation and a preparation method thereof, and relates to the technical field of biological medicines. The oral preparation is prepared from the following raw materials: vitamin B12, internal factors, chickpea protein, III type collagen peptide, a pH regulator, an antioxidant and a dispersing agent. The vitamin B12 and the internal factors are taken as active ingredients, the utilization degree of the vitamin B12 is remarkably improved through the specific proportion of the vitamin B12 and the internal factors, and the prepared reagent meets the requirement that the reagent is not released in a gastric acid environment and then is slowly released in the intestinal tract, and has a remarkable effect on the anemia problem caused by deficiency of the vitamin B12 after the gastric resection operation; and the stability of the medicine is high.

The invention discloses a chlamydomonas reinhardtii source organism iron steady state regulator and application thereof, and belongs to the technical field of biology. The chlamydomonas reinhardtii hydroxyproline-rich glycoprotein or the protein component thereof disclosed by the invention can activate low-oxygen inducible factor signal channels of intestinal tracts, livers and kidneys, and up-regulate the expression of iron absorption transporters such as a divalent metal ion carrier 1, duodenum cytochrome b, membrane iron transporters and ferrous oxidase in intestinal epithelial cells; according to the present invention, the liver hepcidin overexpression caused by inflammation can be inhibited, the generation of erythropoietin in the liver and the kidney can be promoted so as to stimulate the absorption of the body on the iron nutrient, and the compound can be used in the anemia improving health food and the anemia improving drug. The organism iron homeostasis regulator adopted by the invention is derived from microalgae food, so that compared with a conventional artificially synthesized organism iron homeostasis regulator drug, the organism iron homeostasis regulator has the advantage of no toxic or side effect.

The present application relates to the use of idasanutlin, or a pharmaceutically acceptable salt, a solvate, an isomer, or a functional derivative thereof for the treatment of hemoglobinopathies, including sickle cell disease, thalassemia, sickle cell beta thalassemia (Hb S / β Th), and leukocytosis as well as myeloproliferative conditions, polycythemia, and acute and chronic hemolytic anemia. It was found that idasanutlin increases HbF levels in multipotent erythroleukemia, hematopoietic stem cells, and sickle cell disease cells to provide another therapy for treatment of sickle cell disease.